Managers / Q2 2023 · view latest →
Krensavage Asset Management, LLC
CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582
Summary
Krensavage Asset Management, LLC reported $316M in U.S.-listed holdings across 12 positions for Q2 2023.
Its largest position, BIIB, represents 16.0% of the portfolio.
The book was largely unchanged from Q1 2023.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 92.3% · $291M
- Other · 7.7% · $24M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| KODKODIAK SCIENCES INC | TRIMMED | −114.9K | 344.6K | −$471,000 | $2M |
| ALKSALKERMES PLC | TRIMMED | −292.3K | 1.10M | −$5M | $35M |
| ENTAENANTA PHARMACEUTICALS INC | ADDED | +84.3K | 687.6K | −$10M | $15M |
| EMBCEMBECTA CORP | HELD | +8.7K | 1.07M | −$7M | $23M |
| REGNREGENERON PHARMACEUTICALS | HELD | −300 | 59.2K | −$6M | $43M |
| VNDAVANDA PHARMACEUTICALS INC | HELD | +1.4K | 363.0K | −$63,000 | $2M |
| UTHRUNITED THERAPEUTICS CORP | HELD | +605 | 202.7K | −$516,000 | $45M |
| EGRXEAGLE PHARMACEUTICALS INC | HELD | −300 | 113.4K | −$1M | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BIIBBIOGEN INChistory → | COM | 15.96% | $50M | 176.8K |
| 2 | UTHRUNITED THERAPEUTICS CORPhistory → | COM | 14.18% | $45M | 202.7K |
| 3 | REGNREGENERON PHARMACEUTICALShistory → | COM | 13.47% | $43M | 59.2K |
| 4 | EXELEXELIXIS INChistory → | COM | 12.92% | $41M | 2.13M |
| 5 | ALKSALKERMES PLChistory → | COM | 10.94% | $35M | 1.10M |
| 6 | CAHCARDINAL HEALTH INChistory → | COM | 10.60% | $33M | 353.7K |
| 7 | TARO PHARMACEUTICAL INDUS | COM | 7.73% | $24M | 643.1K |
| 8 | EMBCEMBECTA CORPhistory → | COM | 7.33% | $23M | 1.07M |
| 9 | ENTAENANTA PHARMACEUTICALS INChistory → | COM | 4.66% | $15M | 687.6K |
| 10 | VNDAVANDA PHARMACEUTICALS INC | COM | 0.76% | $2M | 363.0K |
| 11 | KODKODIAK SCIENCES INC | COM | 0.75% | $2M | 344.6K |
| 12 | EGRXEAGLE PHARMACEUTICALS INC | COM | 0.70% | $2M | 113.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $256M | 20 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $283M | 18 | Feb 18, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $235M | 17 | Nov 17, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $189M | 15 | Aug 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $181M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $169M | 12 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2024 | $178M | 13 | Nov 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $218M | 13 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $226M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $282M | 12 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $272M | 12 | Nov 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $316M | 12 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $329M | 12 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $324M | 12 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $314M | 14 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $302M | 14 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $290M | 13 | May 17, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $288M | 10 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $319M | 13 | Nov 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $295M | 13 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $289M | 12 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $342M | 12 | Feb 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $314M | 11 | Dec 8, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $368M | 11 | Aug 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2020 | $311M | 13 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $293M | 12 | Feb 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $260M | 10 | Nov 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $308M | 10 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $370M | 12 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.